A Glimpse Into the Future for Unresectable Stage III Non-Small Cell Lung Cancer

Approximately 20% to 25% of patients with non-small cell lung cancer (NSCLC) are diagnosed with stage III disease (TNM eighth edition).1,2 Every patient should be discussed in a multidisciplinary tumor board to review the staging (extent of nodal involvement and mediastinal invasion) and whether a tumor is resectable. Subsequent choices regarding treatment can be very challenging.3 For patients not eligible for surgery, the standard of care is concurrent chemoradiotherapy (CCRT) followed by adjuvant durvalumab.